Synexus Czech s.r.o.

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Amyloidosis3 trials
• Obesity3 trials
• Ulcerative colitis3 trials
• COPD2 trials
• Osteoporosis2 trials
• Atopic dermatitis (eczema)1 trial
• Chronic kidney disease1 trial
• Crohn's disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Psoriasis1 trial
• Type 2 diabetes1 trial

Phase

• Phase 314 trials
• Phase 2/33 trials

Status

• Completed10 trials
• Active, not recruiting6 trials
• Recruiting1 trial

Lead sponsor

• Alnylam Pharmaceuticals Inc.2 trials
• Janssen Research & Development, LLC2 trials
• Pfizer2 trials
• Alnylam Pharmaceuticals1 trial
• Amgen1 trial
• and 9 more

Running trials

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Pfizer· Source

• Active, not recruiting

  Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

  NCT07311850· Phase 3· Pfizer· Source

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  NCT06961214· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518343-38-00· Phase 3· Alnylam Pharmaceuticals Inc.· Source

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Sanofi· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting

Closed trials

• Completed

  A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis

  2024-512417-41-00· Phase 3· Xentria Inc.· Source

• Completed

  A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

  NCT06176560· Phase 3· Faes Farma S.A.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.

  2022-502778-18-00· Phase 3· Polpharma Biologics S.A.· Source

• Completed

  Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis

  NCT05853354· Phase 3· Shandong Boan Biotechnology Co. Ltd.· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Active, not recruiting

  A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518318-25-00· Phase 3· Alnylam Pharmaceuticals Inc.· Source

• Completed

  A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

  NCT04175613· Phase 3· Amgen· Source

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Alnylam Pharmaceuticals· Source